Cancer Research on Prevention and Treatment    2022, Vol. 49 Issue (08) : 827-831     DOI: 10.3971/j.issn.1000-8578.2022.22.0320
|
Research Progress on Hyperthermia and Anti-Tumor Immunity
YIN Zhucheng, LIANG Xinjun
Department of Medical Oncology, Hubei Cancer Hospital, Wuhan 430079, China
Download: PDF(2927 KB)   ( 52 )   HTML ()
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks
Abstract In recent years, with the development of comprehensive tumor therapy, hyperthermia has become one of the important means of cancer treatment. A large number of studies have shown that the removal of tumor cells depends on exogenous treatment methods and the body’s own anti-tumor immune status. Hyperthermia cannot only directly kill tumor cells but also activate the body’s immunity to exhibit an anti-tumor effect. In recent years, with the deepening of tumor research, hyperthermia has been able to create a type I tumor microenvironment with PD-L1 overexpression and enrichment of tumor-infiltrating lymphocytes, complementing the enhancement of immune checkpoint inhibitors. Hyperthermia combined with immunotherapy may offer a new perspective in cancer treatment. The mechanism of tumor hyperthermia and anti-tumor immunity and its clinical application have aroused great interest and become a new research field. This article reviews the relationship between tumor hyperthermia and anti-tumor immunity.
Keywords Hyperthermia      Immunotherapy      Anti-tumor Immunity      Cytokine     
ZTFLH:  R730.5  
Fund:National Natural Science Foundation of China (No. 81772499); Foundation of Health Commission of Hubei Province (No.WJ2021Z001)
Issue Date: 11 August 2022
 Cite this article:   
YIN Zhucheng,LIANG Xinjun. Research Progress on Hyperthermia and Anti-Tumor Immunity[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 827-831.
 URL:  
http://www.zlfzyj.com/EN/10.3971/j.issn.1000-8578.2022.22.0320
http://www.zlfzyj.com/EN/Y2022/V49/I08/827
Service
E-mail this article
E-mail Alert
RSS
Articles by authors
YIN Zhucheng
LIANG Xinjun
[1] Pandey A, Yadav P, Shukla S. Unfolding the role of autophagy
in the cancer metabolism[J]. Biochem Biophys Rep, 2021, 28:
101158.
[2] Elming PB, S?rensen BS, Oei AL, et al. Hyperthermia: The
Optimal Treatment to Overcome Radiation Resistant Hypoxia[J].
Cancers (Basel), 2019, 11(1): 60.
[3] Mantso T, Vasileiadis S, Anestopoulos I, et al. Hyperthermia
induces therapeutic effectiveness and potentiates adjuvant therapy
with non-targeted and targeted drugs in an in vitro model of
human malignant melanoma[J]. Sci Rep, 2018, 8(1): 10724.
[4] Mei X, Ten Cate R, Van Leeuwen CM, et al. Radiosensitization
by Hyperthermia: The Effects of Temperature, Sequence, and
Time Interval in Cervical Cell Lines[J]. Cancers (Basel), 2020,
12(3): 582.
[5] Vítor AC, Huertas P, Legube G, et al. Studying DNA Double-
Strand Break Repair: An Ever-Growing Toolbox[J]. Front Mol
Biosci, 2020, 7: 24.
[6] Lee S, Son B, Park G, et al. Immunogenic Effect of Hyperthermia
on Enhancing Radiotherapeutic Efficacy[J]. Int J Mol Sci, 2018,
19(9): 2795.
[7] Lou J, Zhou Y, Feng Z, et al. Caspase-Independent Regulated
Necrosis Pathways as Potential Targets in Cancer Management[J].
Front Oncol, 2020, 10: 616952.
[8] De Andrade Mello P, Bian S, Savio LEB, et al. Hyperthermia
and associated changes in membrane fluidity potentiate P2X7 activation to promote tumor cell death[J]. Oncotarget, 2017,
8(40): 67254-67268.
[9] Albakova Z, Mangasarova Y. The HSP Immune Network in
Cancer[J]. Front Immunol, 2021, 12: 796493.
[10] McGraw JM, Witherden DA. γδ T cell costimulatory ligands in
antitumor immunity[J]. Explor Immunol, 2022, 2(1): 79-97.
[11] Zhang Y, Gao X, Yan B, et al. Enhancement of CD8+ T-Cell-
Mediated Tumor Immunotherapy via Magnetic Hyperthermia[J].
ChemMedChem, 2022, 17(2): e202100656.
[12] Persano S, Das P, Pellegrino T. Magnetic Nanostructures as
Emerging Therapeutic Tools to Boost Anti-Tumour Immunity[J].
Cancers(Basel), 2021, 13(11): 2735.
[13] Lin C, Chen J. Regulation of immune cell trafficking by febrile
temperatures[J]. Int J Hyperthermia, 2019, 36(sup 1): 17-21.
[14] Garnier L, Gkountidi A-O, Hugues S. Tumor-Associated
Lymphatic Vessel Features and Immunomodulatory Functions[J].
Front Immunol, 2019, 10: 720.
[15] Chen Y, Song Y, Du W, et al. Tumor-associated macrophages: an
accomplice in solid tumor progression[J]. J Biomed Sci, 2019,
26(1): 78.
[16] Wan Mohd Zawawi WFA, Hibma MH, Salim MI, et al.
Hyperthermia by near infrared radiation induced immune cells
activation and infiltration in breast tumor[J]. Sci Rep, 2021, 11(1):
10278.
[17] Rankin LC, Artis D. Beyond Host Defense: Emerging
Functions of the Immune System in Regulating Complex Tissue
Physiology[J]. Cell, 2018, 173(3): 554-567.
[18] Wu SY, Fu T, Jiang YZ, et al. Natural killer cells in cancer biology
and therapy[J]. Mol Cancer, 2020, 19(1): 120.
[19] Zhang C, Hu Y, Shi C. Targeting Natural Killer Cells for Tumor
Immunotherapy[J]. Front Immunol, 2020, 11: 60.
[20] Milani V, Noessner E. Effects of thermal stress on tumor
antigenicity and recognition by immune effector cells[J]. Cancer
Immunol Immunother, 2006, 55(3): 312-319.
[21] Paul S, Lal G. The Molecular Mechanism of Natural Killer Cells
Function and Its Importance in Cancer Immunotherapy[J]. Front
Immunol, 2017, 8: 1124.
[22] Ostberg JR, Dayanc BE, Yuan M, et al. Enhancement of natural
killer (NK) cell cytotoxicity by fever-range thermal stress is
dependent on NKG2D function and is associated with plasma
membrane NKG2D clustering and increased expr‍ession of MICA
on target cells[J]. J Leukoc Biol, 2007, 82(5): 1322-1331.
[23] Dayanc BE. Beachy SH, Ostberg JR, et al. Dissecting the role
of hyperthermia in natural killer cell mediated anti-tumor
responses[J]. Int J Hyperthermia, 2008, 24(1): 41-56.
[24] Hood SP, Foulds GA, Imrie H, et al. Phenotype and Function
of Activated Natural Killer Cells From Patients With Prostate
Cancer: Patient-Dependent Responses to Priming and IL-2
Activation[J]. Front Immunol, 2019, 9: 3169.
[25] Chambers AM, Wang J, Lupo KB, et al. Adenosinergic Signaling
Alters Natural Killer Cell Functional Responses[J]. Front
Immunol, 2018, 9: 2533.
[26] Waldman AD, Fritz JM, Lenardo MJ. A guide to cancer
immunotherapy: from T cell basic science to clinical practice[J].
Nat Rev Immunol, 2020, 20(11): 651-668.
[27] Adnan A, Mu?oz NM, Prakash P, et al. Hyperthermia and Tumor
Immunity[J]. Cancers (Basel), 2021, 13(11): 2507.
[28] Lin C, Zhang Y, Zhang K, et al. Fever Promotes T Lymphocyte
Trafficking via a Thermal Sensory Pathway Involving Heat Shock
Protein 90 and α4 Integrins[J]. Immunity, 2019, 50(1): 137-151.
[29] Umar D, Das A, Gupta S, et al. Febrile temperature change
modulates CD4 T cell differentiation via a TRPV channelregulated
Notch-dependent pathway[J]. Proc Natl Acad Sci U S A,
2020, 117(36): 22357-22366.
[30] Do JS, Kim S, Keslar K, et al. γδ T Cells Coexpressing Gut
Homing α4β7 and αE Integrins Define a Novel Subset Promoting
Intestinal Inflammation[J]. J Immunol, 2017, 198(2): 908-915.
[31] Wang M, Wang S, Desai J, et al. Therapeutic strategies to remodel
immunologically cold tumors[J]. Clin Transl Immunology, 2020,
9(12): e1226.
[32] Anderson KG, Stromnes IM, Greenberg PD. Obstacles Posed
by the Tumor Microenvironment to T cell Activity: A Case for
Synergistic Therapies[J]. Cancer Cell, 2017, 31(3): 311-325.
[33] Li Z, Deng J, Sun J, et al. Hyperthermia Targeting the Tumor
Microenvironment Facilitates Immune Checkpoint Inhibitors[J].
Front Immunol, 2020, 11: 595207.
[34] Newton JM, Flores-Arredondo JH, Suki S, et al. Non-Invasive
Radiofrequency Field Treatment of 4T1 Breast Tumors Induces
T-cell Dependent Inflammatory Response[J]. SciRep, 2018, 8(1):
3474.
[35] Qi X, Yang M, Ma L, et al. Synergizing sunitinib and
radiofrequency ablation to treat hepatocellular cancer by triggering
the antitumor immune response[J]. J Immunother Cancer, 2020,
8(2): e001038.
[36] Duffy AG, Ulahannan SV, Makorova-Rusher O, et al.
Tremelimumab in combination with ablation in patients with
advanced hepatocellular carcinoma[J]. J Hepatol, 2017, 66(3):
545-551.
[37] Wang X, Liu G, Chen S, et al. Combination therapy with PD-1
blockade and radiofrequency ablation for recurrent hepatocellular
carcinoma: a propensity score matching analysis[J]. Int J
Hyperthermia, 2021, 38(1): 1519-1528.
[38] Chen Q, Xu L, Liang C, et al. Photothermal therapy with immuneadjuvant
nanoparticles together with checkpoint blockade for
effective cancer immunotherapy[J]. Nat Commun, 2016, 7: 13193.
[39] Huang L, Li Y, Du Y, et al. Mild photothermal therapy potentiates
anti-PD-L1 treatment for immunologically cold tumors via an allin-
one and all-in-control strategy[J]. Nat Commun, 2019, 10(1):
4871.
[40] Johannsen M, Gneveckow U, Taymoorian K, et al. Morbidity and
quality of life during thermotherapy using magnetic nanoparticles
in locally recurrent prostate cancer: results of a prospective phase
I trial[J]. Int J Hyperthermia, 2007, 23(3): 315-323.
[41] Maier-Hauff K, Ulrich F, Nestler D, et al. Efficacy and safety
of intratumoral thermotherapy using magnetic iron-oxide
nanoparticles combined with external beam radiotherapy on
patients with recurrent glioblastoma multiforme[J]. J Neurooncol,
2011, 103(2): 317-324.
Related articles from Frontiers Journals
[1] YANG Junyuan, CAI Hongbing. Countermeasures and Mechanisms of Drug Resistance in Immunotherapy for Cervical Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 886-892.
[2] YIN Zhucheng, LIANG Xinjun. Research Progress on Combined Immunotherapy for Microsatellite Stable Colorectal Cancer#br#[J]. Cancer Research on Prevention and Treatment, 2022, 49(09): 977-981.
[3] CAO Guangwen. Theoretical Update of Cancer Evo-Dev and Its Role in Targeted Immunotherapy for Hepatocellular Carcinoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 747-755.
[4] KANG Yikun, YUAN Peng. Advances in Treatment of Triple Negative Breast Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 812-819.
[5] XIA Siyu, ZHAO Zitong, LI Li. Correlation Between STK11 Gene Mutation and Immunotherapy of Non-small Cell Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(08): 850-854.
[6] CHEN Weichang, SHI Tongguo, ZHU Jinghan, SUN Linqing, LI Juntao. Progress on Immunotherapy of Gastrointestinal Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 639-643.
[7] JIN Tongtong, ZHOU Chuan, WANG Chao, DA Zijian, ZHOU Fenghai, . Research Hotspots and Frontiers of Immunotherapy for Prostate Cancer: A Visual Analysis[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 667-674.
[8] WU Wei, JING Doudou, CAO Li, PU Feifei, SHAO Zengwu. Current Status and Prospects of Immunotherapy for Osteosarcoma[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 721-726.
[9] CHEN Bojin, HU Xingyi, ZHAO Jingwen, ZHENG Aihong. Current Status of Immunotherapy in Neoadjuvant Therapy for Gastric Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(07): 727-732.
[10] ZHANG Jianning, LIU Congwei. Progress of Novel Treatment Options for Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 505-513.
[11] SUN Junzhao, CHENG Gang, ZHANG Jianning. Advances in Treatment of Brain Metastasis from Lung Cancer[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 522-527.
[12] ZHANG Yu, HE Kunyu, FENG Shiyu. Current Progress in Treatment of Glioma[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 528-534.
[13] LI Yuxin, JIN Feng, . Immune Checkpoint PD-1-based Mechanisms of Tumor Immune Resistance and Strategies for Re-treatment After Drug Resistance[J]. Cancer Research on Prevention and Treatment, 2022, 49(06): 546-551.
[14] HOU Jian, WANG Junying. Research Progress of Immune Microenvironment in Multiple Myeloma[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 375-378.
[15] GUO Yang, WU Suqing, WEN Zhaohui. Application Progress of Metal-organic Frameworks in Tumors Therapy[J]. Cancer Research on Prevention and Treatment, 2022, 49(05): 472-477.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed